Aripirazole—Olanzapine Combination for Treatment of Schizophrenia

Duggal, Harpreet S.

doi:10.1177/070674370404900213

Cited by 27 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is anticipated that the Phase 3 results of the Clinical Antipsychotic Trials of Intervention Effectiveness (Lieberman et al 2005) will provide additional information on switching to open-label aripiprazole from a variety of blinded antipsychotics or from open-label clozapine. The issue of using aripiprazole as an augmenting agent to other antipsychotics has not yet been reported in a randomized, double-blind, clinical trial, although case reports exist of combinations of olanzapine or clozapine with aripiprazole resulting in increased efficacy or tolerability (Duggal 2004; Lim et al 2004; Ziegenbein et al 2005; Clarke et al 2006; Henderson et al 2006). However, addition of aripiprazole to first- and second-generation antipsychotics has also been associated with exacerbation of symptoms (DeQuardo 2004; Reeves and Mack 2004; Ramaswamy et al 2004; Barnas et al 2005; Glick et al 2006).…”

Section: Is Aripiprazole Worth Using?mentioning

confidence: 99%

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Citrome¹

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Aripiprazole has been approved by regulatory agencies for the treatment of schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized clinical trials have established the efficacy and tolerability of aripiprazole within the dose range of 10-30 mg/day for schizophrenia, and 15-30 mg/day for manic or mixed states associated with bipolar I disorder. Relatively few comparative trials with other secondgeneration antipsychotics have been published for schizophrenia, with none available for bipolar disorder. The evidence so far suggests that in terms of efficacy for schizophrenia, aripiprazole is superior to placebo and haloperidol (long term), similar to perphenazine and risperidone, and inferior to olanzapine. Its tolerability profile in patients with schizophrenia appears superior to haloperidol, perphenazine, risperidone, and olanzapine. Efficacy in treating manic or mixed states was established in placebo-controlled trials. Among some patients with bipolar disorder, akathisia and gastrointestinal (GI) complaints can emerge at the start of treatment; however, the GI symptoms were time-limited in many instances. Appropriate dosing may also be important in individualizing therapy to improve tolerability, with lower starting doses becoming more important when adding to, or switching from, another antipsychotic. Aripiprazole appears to have a low propensity for weight gain, a favorable metabolic profile, and no association with hyperprolactinemia.

show abstract

Section: Is Aripiprazole Worth Using?mentioning

confidence: 99%

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Citrome¹

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

show abstract

“…Recent reports describing antipsychotic medication use in current practice settings reveal a high prevalence of combination therapy with multiple antipsychotic medication regimens [15][16][17] and the use of high-dose therapies. [18][19][20] Although randomized placebo-controlled trials are lacking, therapies that combine antipsychotic medications may hold promise for certain patient subtypes, [21][22][23][24] and growing evidence suggests a benefit of high-dose therapy for some patients with treatment-resistant disease. 25,26 However, studies describing the dose-response relationship pertaining to the efficacy and toxicity of the atypical antipsychotics are lacking.…”

mentioning

confidence: 99%

Prescribing of Antipsychotic Medication in a Medicaid Population: Use of Polytherapy and Off-Label Dosages

Kogut¹,

Yam²,

Dufresne³

2005

JMCP

View full text Add to dashboard Cite

“…The combination of aripiprazole with other antipsychotics has been less studied [13]. In our sample, we have included different combinations of antipsychotics, including both atypical and typical antipsychotics, with different range of doses and ways of administration (see Table 4).…”

Section: Discussionmentioning

confidence: 99%

Combination of Aripiprazole and Other Psychopharmacological Treatments in Resistant and Multi-Resistant Patients

Gómez

Fuste²,

Coronas³

et al. 2008

CDS

View full text Add to dashboard Cite

Mean follow-up 20.4 days. Main diagnosis was schizophrenia (40%) and mean dose of aripiprazole was 25 mg/d. Resistant patients received initially multiple psychotropics (mean 3.3) and their functional status was very low. A significant functional improvement was observed after admission in most (12) of them. Only three patients experienced mild to moderate improvement; another three patients showed extrapyramidal symptoms. No dermatological reactions or adverse effects were observed with lamotrigine association. DISCUSIONS: The combination of aripiprazole with other psychotropics was well tolerated. No significant new adverse reactions were observed. In a short term follow-up, our results show a good tolerability of aripiprazole in combination with other psychotropics of different groups.

show abstract

Aripirazole—Olanzapine Combination for Treatment of Schizophrenia

Cited by 27 publications

References 10 publications

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Prescribing of Antipsychotic Medication in a Medicaid Population: Use of Polytherapy and Off-Label Dosages

Combination of Aripiprazole and Other Psychopharmacological Treatments in Resistant and Multi-Resistant Patients

Contact Info

Product

Resources

About